0001209191-17-034073.txt : 20170519
0001209191-17-034073.hdr.sgml : 20170519
20170519185616
ACCESSION NUMBER: 0001209191-17-034073
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170516
FILED AS OF DATE: 20170519
DATE AS OF CHANGE: 20170519
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 79 T.W. ALEXANDER DRIVE
STREET 2: 4501 RESEARCH COMMONS, SUITE 100
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: P. O. BOX # 110341
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RUDNICK SETH
CENTRAL INDEX KEY: 0001184420
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 17859419
MAIL ADDRESS:
STREET 1: 7100 WEST CREDIT AVENUE, SUITE 101
STREET 2: C/O ARALEZ PHARMACEUTICALS
CITY: MISSISSAUGA
STATE: A6
ZIP: L5N 0E4
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2017-05-16
2017-05-16
0
0001560241
G1 Therapeutics, Inc.
GTHX
0001184420
RUDNICK SETH
C/O G1 THERAPEUTICS, INC.
79 T.W. ALEXANDER DRIVE
RESEARCH TRIANGLE PARK
NC
27709
1
0
0
0
Stock Option (Right to Buy)
0.30
2025-02-27
Common Stock
13890
D
The shares underlying this option vested as to 25% of the shares on February 28, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. A portion this stock option was exercised exercised prior to the date of the original filing.
The number of underlying shares of common stock and the exercise price reported reflect a 1-for-3 reverse stock split of the Issuer's common stock effected on May 11, 2017.
This amendment is being filed to correct the number of shares underlying the stock option. The original filing on May 16, 2017 noted that the number of shares underlying the stock option was 83,333. The correct number is 13,890.
/s/ Caroline G. Gammill, attorney-in-fact
2017-05-19